Core Insights - Quest Diagnostics Incorporated (DGX) is a leader in diagnostic information services, providing a range of testing for various health conditions [1][2] - The company has a market capitalization of $20.31 billion, classifying it as a "large-cap" stock [2] Financial Performance - In Q3 2025, DGX reported net revenues of $2.82 billion, a 13.1% year-over-year increase, surpassing analysts' expectations of $2.72 billion [5] - The company's adjusted EPS rose by 13% year-over-year to $2.60, exceeding the expected $2.51 [5] - Following strong results, DGX raised its fiscal 2025 net revenue guidance to a range of $10.96 billion to $11 billion and adjusted EPS guidance to $9.76 to $9.84 [6] Stock Performance - DGX's shares reached a 52-week high of $197.55 in October but have since declined by 7.6% [3] - Over the past three months, DGX's stock has seen a marginal decline, while the State Street Health Care Select Sector SPDR ETF (XLV) gained 11.6% [3] - In the last six months, DGX's stock gained approximately 2%, compared to a 12.6% rise in the ETF [4] - Over the past 52 weeks, DGX's stock increased by 17%, outperforming the Health Care ETF's 9.3% return [4]

Core Insights - Quest Diagnostics will present its strategy, performance, and market trends at the Jefferies Healthcare Services Conference on September 29, 2025 [1] - The presentation will include a live webcast available on the company's investor relations page, with an archived version accessible for 24 hours post-event [2] - Quest Diagnostics serves a significant portion of the U.S. population, providing diagnostic insights that empower health management [3] Company Overview - Quest Diagnostics is a leader in diagnostic information services, aiming to improve health outcomes through laboratory testing [3] - The company operates one of the largest databases of de-identified clinical lab results, which aids in disease identification and treatment [3] - Annually, Quest Diagnostics serves one in three adult Americans and half of the physicians and hospitals in the U.S. [3] Recent Developments - Quest Diagnostics has launched an advanced pharmacogenomic (PGx) laboratory offering, enhancing its service portfolio [4] - The 2025 Quest Diagnostics Drug Testing Index indicates a significant increase in fentanyl positivity in random tests compared to pre-employment screenings [5]